Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in J Invest Dermatol Retrieve available abstracts of 70 articles: HTML format

Single Articles

May 2025
1. KENTLEY J, Kurtansky N, Jain M, Cordova M, et al
   Non-invasive diagnosis of melanoma using machine learning and reflectance confocal microscopy.
   J Invest Dermatol. 2025 May 29:S0022-202X(25)00539.
   PubMed    
   
   
   
2. BURKE OM, Ma F, Huang J, Kirsner RS, et al
   Melanoma Incidence and Survival: A SEER Database Study.
   J Invest Dermatol. 2025 May 27:S0022-202X(25)00527.
   PubMed    
   
   
   
3. PERES J, Damerell V, Chauhan J, Popovic A, et al
   Corrigendum to 'TBX3 Promotes Melanoma Migration by Transcriptional Activation of ID1, which Prevents Activation of E-Cadherin by MITF' Journal of Investigative Dermatology, Volume 141, Issue 9, September 2021, Pages 2250-2260.
   J Invest Dermatol. 2025 May 21:S0022-202X(24)03018.
   PubMed    
   
   
   
4. POLO-SILVEIRA L, Dusza SW, Kentley J, Marchetti MA, et al
   Cutaneous Melanoma Risk Assessment Among Individuals with a High-Risk Nevus Phenotype.
   J Invest Dermatol. 2025 May 13:S0022-202X(25)00478.
   PubMed    
   
   
   April 2025
5. DONG L, Wu N, Cai Z, Yan S, et al
   Tolerogenic monocyte-derived langerhans cells promote melanoma progression and immunotherapy resistance through AhR-COX2 activation.
   J Invest Dermatol. 2025 Apr 9:S0022-202X(25)00404.
   PubMed     Abstract available
   
   
   
6. SU L, Wang D, Purwin TJ, Ran S, et al
   Selective USP7 inhibition synergizes with MEK1/2 inhibitor to enhance immune responses and potentiate anti-PD-1 therapy in NRAS mutant melanoma.
   J Invest Dermatol. 2025 Apr 7:S0022-202X(25)00384.
   PubMed     Abstract available
   
   
   
7. XIE J, Ma C, Zhao S, Wu D, et al
   Deubiquitination by USP7 Stabilizes JunD and Activates AIFM2 (FSP1) to Inhibit Ferroptosis in Melanoma.
   J Invest Dermatol. 2025 Apr 3:S0022-202X(25)00381.
   PubMed     Abstract available
   
   
   March 2025
8. HAUGH AM, Fisher DE, Lawrence DP
   Tumor-Infiltrating Lymphocyte Therapy for Melanoma Has Arrived (at Last).
   J Invest Dermatol. 2025 Mar 27:S0022-202X(24)03033.
   PubMed    
   
   
   
9. ZHENG L, Soyer HP, Janda M, Jayasinghe D, et al
   An overview of data analysis approaches and biases in unveiling the impact of COVID 19 on melanoma diagnosis.
   J Invest Dermatol. 2025 Mar 25:S0022-202X(25)00371.
   PubMed    
   
   
   
10. MARGUIER A, Mathiot J, NDao B, Wespiser M, et al
    TIE-2 expressing monocytic myeloid-derived suppressor cells are involved in resistance to anti-PD-1 therapy mediated by angiopoietin 2 in melanoma patients.
    J Invest Dermatol. 2025 Mar 18:S0022-202X(25)00327.
    PubMed    
    
    
    
11. MA K, Shafique N, Tortorello G, Dheer A, et al
    Significance of Prognostic Factors Across Tumor Thicknesses in Melanoma: A National Cohort Study.
    J Invest Dermatol. 2025 Mar 12:S0022-202X(25)00321.
    PubMed    
    
    
    
12. CHANG J, Shin K, Lewis JM, Suh HW, et al
    Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol-Coated Biodegradable Nanoparticles.
    J Invest Dermatol. 2025;145:593-604.
    PubMed     Abstract available
    
    
    February 2025
13. AZIMI A, Bi L, Bonfil A, Teh R, et al
    Integrated analysis of proteomic and dermoscopy imaging data improves non-invasive classification of benign nevi and melanoma.
    J Invest Dermatol. 2025 Feb 13:S0022-202X(25)00102.
    PubMed    
    
    
    
14. WHITESIDE TL
    Transfer of Oncologic Signals from Melanoma Cells to Benign Melanocytes by Circulating Tumor-Derived Extracellular Vesicles.
    J Invest Dermatol. 2025 Feb 7:S0022-202X(25)00025.
    PubMed    
    
    
    
15. WONG ZY, Ou KQ, Wong ZN, Faderani R, et al
    Comment on "Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity.".
    J Invest Dermatol. 2025 Feb 4:S0022-202X(25)00005.
    PubMed    
    
    
    January 2025
16. MULLER C, Tschandl P, Rinner C, Kyrgidis A, et al
    The BRAAFF-Annotated Acral Lesions Dataset (BALD): A curated set of dermatoscopic images of acral melanoma and nevi from various sources.
    J Invest Dermatol. 2025 Jan 17:S0022-202X(25)00021.
    PubMed    
    
    
    
17. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy.
    J Invest Dermatol. 2025 Jan 13:S0022-202X(25)00004.
    PubMed    
    
    
    
18. MENG Y, Zhou Q, Dian Y, Zeng F, et al
    Ferroptosis: A Targetable Vulnerability for Melanoma Treatment.
    J Invest Dermatol. 2025 Jan 8:S0022-202X(24)03024.
    PubMed     Abstract available
    
    
    
19. TRIBBLE JT, Brownell I, Cahoon EK, Sargen MR, et al
    A comparative study of Merkel cell carcinoma and melanoma incidence and survival in the United States, 2000-2021.
    J Invest Dermatol. 2025 Jan 6:S0022-202X(25)00001.
    PubMed     Abstract available
    
    
    December 2024
20. LEE KJ, Kao YC, Smit DJ, Betz-Stablein B, et al
    Mitochondrial deletion(4977) abundance in melanoma-adjacent skin.
    J Invest Dermatol. 2024 Dec 24:S0022-202X(24)03026.
    PubMed    
    
    
    
21. THAKKER S, Arbesman J, Klein JC, Sunshine JC, et al
    Three-Dimensional Nuclear Architecture and Genomic Structural Variations in Melanoma.
    J Invest Dermatol. 2024 Dec 24:S0022-202X(24)03032.
    PubMed    
    
    
    
22. USOLTSEV D, Njauw CN, Ji Z, Kumar R, et al
    Analysis of variants induced by combined ex vivo irradiation and in vivo tumorigenesis suggests a role for the ZNF831 p.R1393Q mutation in cutaneous melanoma development.
    J Invest Dermatol. 2024 Dec 13:S0022-202X(24)03015.
    PubMed     Abstract available
    
    
    
23. HAO J, Xu H, Luo M, Yu W, et al
    Corrigendum to The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy [Journal of Investigative Dermatology, Volume 138, Issue 1, January 2018, Pages 159-170].
    J Invest Dermatol. 2024 Dec 6:S0022-202X(24)02184.
    PubMed    
    
    
    November 2024
24. LIU X, Janknecht R, Asadbeigi SN, Perry L, et al
    The influence of melanoma extracellular vesicles on benign melanocytes: a role for PRAME in modulation of the tumor microenvironment.
    J Invest Dermatol. 2024 Nov 26:S0022-202X(24)02959.
    PubMed     Abstract available
    
    
    
25. SEYRAN B, Avila I, Galvan C, Robles G, et al
    Inhibition of pyruvate oxidation diminishes melanoma progression.
    J Invest Dermatol. 2024 Nov 18:S0022-202X(24)02902.
    PubMed    
    
    
    
26. GUTIERREZ-GARCIA C, Robles-Espinoza CD
    MicroRNA Quantification as an Accurate and Cost-Effective Method to Diagnose Acral Melanoma.
    J Invest Dermatol. 2024 Nov 1:S0022-202X(24)02098.
    PubMed    
    
    
    
27. WEI G, Tran MM, Orsillo L, Mirza FN, et al
    A Geospatial Analysis of the Association between Access to Tanning Bed Facilities and Melanoma in the United States New England Region.
    J Invest Dermatol. 2024 Nov 1:S0022-202X(24)02172.
    PubMed     Abstract available
    
    
    September 2024
28. MEANT A, Moussa O, Lebeau B, Goncalves C, et al
    Combined inhibition of MNK signaling and BET proteins reveals TGM2 as a novel vulnerability in melanoma.
    J Invest Dermatol. 2024 Sep 30:S0022-202X(24)02160.
    PubMed    
    
    
    
29. SOLER-SAEZ I, Karz A, Hidalgo MR, Gomez-Cabanes B, et al
    Unveiling common transcriptomic features between melanoma brain metastases and neurodegenerative diseases.
    J Invest Dermatol. 2024 Sep 24:S0022-202X(24)02149.
    PubMed     Abstract available
    
    
    
30. CHHABRA G, Ahmad N
    Mystery of Melanotransferrin in Melanoma.
    J Invest Dermatol. 2024 Sep 14:S0022-202X(24)01994.
    PubMed    
    
    
    August 2024
31. RUTJES C, Mothershaw A, D'Alessandro BM, Primiero CA, et al
    Combining Automated Lesion Risk And Change Assessment Improves Melanoma Detection: A Retrospective Accuracy Study.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02060.
    PubMed    
    
    
    
32. DEACON DC, Stubben C, Marcacci E, Stone CJ, et al
    Classification of Cutaneous Melanoma and Melanocytic Nevi with microRNA Ratios is Preserved in the Acral Melanoma Subtype.
    J Invest Dermatol. 2024 Aug 23:S0022-202X(24)02063.
    PubMed    
    
    
    July 2024
33. GAUDEL C, Pisibon C, Soysouvanh F, Giuliano S, et al
    Loss of LYN is frequent in targeted-therapy resistant melanoma cells and favors metastatic properties.
    J Invest Dermatol. 2024 Jul 19:S0022-202X(24)01913.
    PubMed    
    
    
    
34. HASSEL JC, Stanhope S, Greenshields-Watson A, Machiraju D, et al
    Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action.
    J Invest Dermatol. 2024 Jul 15:S0022-202X(24)01886.
    PubMed     Abstract available
    
    
    
35. LATONI DI, Geller A, Semenov YR, Ji Z, et al
    Geotemporal analysis of melanoma incidence and mortality identifies distinct clusters of trends within the United States between 2001-2019.
    J Invest Dermatol. 2024 Jul 7:S0022-202X(24)01874.
    PubMed     Abstract available
    
    
    June 2024
36. CLAUWAERT V, Verhaeghe E, De Schepper S, Haspeslagh M, et al
    Clinicopathologically Defined Naevus Subtypes and Melanoma Risk.
    J Invest Dermatol. 2024 Jun 26:S0022-202X(24)01868.
    PubMed     Abstract available
    
    
    
37. JANDOVA J, Wondrak GT
    Melanotransferrin (MELTF, MFI2, CD228) expression attenuates malignant melanoma progression in the A375-Luc2 murine metastasis model and human patients.
    J Invest Dermatol. 2024 Jun 21:S0022-202X(24)01864.
    PubMed    
    
    
    
38. KAO YC, Stark MS
    Challenging the Lymph Node Progression Model of Melanoma.
    J Invest Dermatol. 2024 Jun 20:S0022-202X(24)00385.
    PubMed    
    
    
    
39. OLSEN CM, Pandeya N, Miranda-Filho A, Rosenberg PS, et al
    Does sex matter? Temporal analyses of melanoma trends among men and women suggest etiologic heterogeneity.
    J Invest Dermatol. 2024 Jun 17:S0022-202X(24)01500.
    PubMed     Abstract available
    
    
    May 2024
40. NARANPANAWA N, Jayasinghe D, Sturm RA, Betz-Stablein B, et al
    Automated Detection of Pigmented Iris Freckles using a Deep Neural Network for Cutaneous Melanoma Risk.
    J Invest Dermatol. 2024 May 30:S0022-202X(24)00444.
    PubMed    
    
    
    April 2024
41. RANDERSON-MOOR J, Davies J, Harland M, Nsengimana J, et al
    Systemic inflammation, the peripheral blood transcriptome and primary melanoma.
    J Invest Dermatol. 2024 Apr 5:S0022-202X(24)00275.
    PubMed     Abstract available
    
    
    
42. BEZROOKOVE V, Kianian S, McGeever L, Jones R, et al
    The molecular evolution of melanoma distant metastases.
    J Invest Dermatol. 2024 Apr 4:S0022-202X(24)00271.
    PubMed     Abstract available
    
    
    March 2024
43. MOHAMMED NBB, Lau LS, Souchak J, Qiu S, et al
    Tumor-intrinsic galectin-3 suppresses melanoma metastasis.
    J Invest Dermatol. 2024 Mar 6:S0022-202X(24)00169.
    PubMed     Abstract available
    
    
    February 2024
44. OLSEN CM, Pandeya N, Whiteman DC
    Trends in age at melanoma diagnosis according to thickness and histologic subtype have implications for causality and control.
    J Invest Dermatol. 2024 Feb 21:S0022-202X(24)00116.
    PubMed    
    
    
    
45. ROOKER A, Ouwerkerk W, Bekkenk MW, Luiten RM, et al
    The Risk of Keratinocyte Cancer in Vitiligo and the Potential Mechanisms Involved.
    J Invest Dermatol. 2024;144:234-242.
    PubMed     Abstract available
    
    
    January 2024
46. COLLENNE J, Monnier J, Iguernaissi R, Nawaf M, et al
    Fusion between an algorithm based on the characterization of melanocytic lesions asymmetry with an ensemble of CNN for melanoma detection.
    J Invest Dermatol. 2024 Jan 29:S0022-202X(24)00078.
    PubMed     Abstract available
    
    
    
47. JEREMIAN R, Lytvyn Y, Fotovati R, Georgakopoulos JR, et al
    Distinct signatures of mitotic age acceleration in cutaneous melanoma and acquired melanocytic nevi.
    J Invest Dermatol. 2024 Jan 28:S0022-202X(24)00083.
    PubMed    
    
    
    
48. NAIMY S, Solberg JBK, Kuczek DE, Lovendorf MB, et al
    Comparative quantitative proteomic analysis of melanoma subtypes, nevus-associated melanoma, and corresponding nevi.
    J Invest Dermatol. 2024 Jan 5:S0022-202X(23)03211.
    PubMed     Abstract available
    
    
    November 2023
49. LEE KJ, Soyer HP, Stark MS
    The Skin Molecular Ecosystem Holds the Key to Nevogenesis and Melanomagenesis.
    J Invest Dermatol. 2023 Nov 1:S0022-202X(23)02918.
    PubMed     Abstract available
    
    
    September 2023
50. LIOPYRIS K, Navarrete-Dechent C, Marchetti MA, Rotemberg V, et al
    Expert agreement on the presence and spatial localization of melanocytic features in dermoscopy.
    J Invest Dermatol. 2023 Sep 7:S0022-202X(23)02577.
    PubMed     Abstract available
    
    
    
51. HAN JH, Lee S, Ju HJ, Kim M, et al
    Automated Mass Screening for Comorbidities of Vitiligo Using the National Health Insurance Database.
    J Invest Dermatol. 2023;143:1717-1723.
    PubMed     Abstract available
    
    
    August 2023
52. FERRER CC, Marguet T, Vanwonterghem L, Erbek S, et al
    Serum IGF1 is a prognostic marker for resistance to targeted therapies and a predictive marker for anti-IGF1R therapy in melanoma.
    J Invest Dermatol. 2023 Aug 12:S0022-202X(23)02499.
    PubMed    
    
    
    
53. VESELY MD, Kidacki M, Gaule P, Gupta S, et al
    Immune inhibitory molecule PD-1H (VISTA) colocalizes with CD11b myeloid cells in melanoma and is associated with poor outcomes.
    J Invest Dermatol. 2023 Aug 7:S0022-202X(23)02483.
    PubMed     Abstract available
    
    
    
54. MEHTA PP, Sun M, Betz-Stablein B, Halpern A, et al
    Improving Artificial Intelligence-Based Diagnosis on Pediatric Skin Lesions.
    J Invest Dermatol. 2023;143:1423-1429.
    PubMed     Abstract available
    
    
    July 2023
55. AHMED F, Lim R, Moseley I, Hoang M, et al
    Neighborhood-level Socioeconomic Predictors of Melanoma Thickness, Ulceration, and Metastasis at a Rhode Island Academic Center.
    J Invest Dermatol. 2023 Jul 3:S0022-202X(23)02403.
    PubMed    
    
    
    
56. PHUNG M, Muralidharan V, Rotemberg V, Novoa RA, et al
    Best Practices for Clinical Skin Image Acquisition in Translational Artificial Intelligence Research.
    J Invest Dermatol. 2023;143:1127-1132.
    PubMed     Abstract available
    
    
    May 2023
57. TORCHIA D
    Correspondence concerning PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma.
    J Invest Dermatol. 2023 May 24:S0022-202X(23)02127.
    PubMed    
    
    
    
58. GUO Z, Liu Q, Lan S, Niu N, et al
    Clinicopathological Features and Prognosis of Melanoma in Northeast China: a region-based cohort study of 229 consecutive cases.
    J Invest Dermatol. 2023 May 17:S0022-202X(23)02069.
    PubMed     Abstract available
    
    
    
59. FERGUSON J, Eleftheriadou V, Nesnas J
    RISK OF MELANOMA AND NON-MELANOMA SKIN CANCER IN PEOPLE WITH VITILIGO: UK POPULATION-BASED COHORT STUDY.
    J Invest Dermatol. 2023 May 3:S0022-202X(23)02047.
    PubMed     Abstract available
    
    
    
60. KANG Y, Ji Z, Li H, Tsao H, et al
    Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.
    J Invest Dermatol. 2023;143:842-853.
    PubMed     Abstract available
    
    
    April 2023
61. AKTARY Z, Raymond JH, Pouteaux M, Delmas V, et al
    Derivation and Use of Cell Lines from Mouse Models of Melanoma.
    J Invest Dermatol. 2023;143:538-544.
    PubMed     Abstract available
    
    
    March 2023
62. MAROCCHI F, Palluzzi F, Nicoli P, Melixetian M, et al
    Actionable genetic screens unveil targeting of AURKA, MEK and fatty acid metabolism as an alternative therapeutic approach for advanced melanoma.
    J Invest Dermatol. 2023 Mar 30:S0022-202X(23)01952.
    PubMed     Abstract available
    
    
    
63. EDDY K, Gupta K, Pelletier JC, Isola AL, et al
    A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY.
    J Invest Dermatol. 2023 Mar 28:S0022-202X(23)01951.
    PubMed     Abstract available
    
    
    
64. LEICHNER GS, Schweitzer I, Dror S, Levin L, et al
    Primary melanoma miRNAs trafficking induce lymphangiogenesis.
    J Invest Dermatol. 2023 Mar 17:S0022-202X(23)01836.
    PubMed     Abstract available
    
    
    
65. CHAGANI S, De Macedo MP, Carapeto F, Wang F, et al
    MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA.
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00164.
    PubMed     Abstract available
    
    
    
66. ERIKSSON I, Vainikka L, Waster P, Ollinger K, et al
    Lysosomal function and intracellular position determine the malignant phenotype in malignant melanoma.
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00171.
    PubMed     Abstract available
    
    
    February 2023
67. JOHANSSON PA, Palmer JM, Hamilton HR, Whiteman DC, et al
    Germline Variants in Childhood Cutaneous Melanoma.
    J Invest Dermatol. 2023 Feb 28:S0022-202X(23)00155.
    PubMed    
    
    
    
68. WANG G, Zeng D, Sweren E, Miao Y, et al
    m6A RNA methylation correlates with immune microenvironment and immunotherapy response of melanoma.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00095.
    PubMed     Abstract available
    
    
    
69. RIBERO S, Lambertini M, Ferracin M, Dika E, et al
    Non-Coding RNA Investigations in Cutaneous Melanoma: a Step forward in Discovering Novel Biomarkers.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00088.
    PubMed    
    
    
    October 2022
70. LUU YT, Luo Q, Horner MJ, Shiels M, et al
    Risk of nonkeratinocyte skin cancers in people living with HIV during the era of antiretroviral therapy.
    J Invest Dermatol. 2022 Oct 7. pii: S0022-202X(22)01942.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.